falsefalse

Expert Insights Into the Management of MPNs - Episode 2

Risk Assessment for Patients with Polycythemia Vera (PV)

, , ,

Dr Jamile Shammo describes how risk is assessed for patients with polycythemia vera.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: An Overview of Myeloproliferative Neoplasms (MPNs)
    Now Viewing
    EP. 2: Risk Assessment for Patients with Polycythemia Vera (PV)
    EP. 3: Current Treatment Landscape for Patients With PV
    EP. 4: Selecting a Frontline Therapy for Patients With PV
    EP. 5: Ruxolitinib for the Management of PV
    EP. 6: Ropeginterferon alfa-2b for the Treatment of PV
    EP. 7: Reviewing the Types of Myelofibrosis
    EP. 8: The Role of Transplant in the Treatment of Patients With MF
    EP. 9: COMFORT-I and COMFORT-II Data Review
    EP. 10: Pacritinib and Fedratinib for the Treatment of MF
    EP. 11: Sequencing Therapies in Patients with MF
    EP. 12: Considering Toxicities and Side Effects of JAK Inhibitors in Patients with MF
    EP. 13: Symptom Monitoring in Patients with MF
    EP. 14: Exploring the Future of MF Treatment

    Related Content:

    Expert Insights Into the Management of MPNsOncLive Peer Exchange® Myeloproliferative Neoplasms
    Future of Bispecifics and CAR T in R/R MM
    Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM
    Comprehensive Biomarker Testing in Early-Stage NSCLC: Identifying Gaps, Challenges, and Strategies for Improvement
    x